Cardinal Health Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Cardinal Health Inc (CAH) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Cardinal Health Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 250,735M vs 1,317,618M combined for tracked competitors (16.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-2.8% annualized vs trailing 12 months), vs decelerating (-4.7%) for its tracked peer group.
- Growth: Cardinal Health Inc generated 11.1% revenue growth year over year in Q3 2026, vs 5.3% for its tracked competitors combined.
- Profitability: Its 0.6% net margin compares with 3.1% for the peer group.
- Scale: Cardinal Health Inc ranks #4 of 16 companies by market capitalization in the Pharmacy Services & Retail Drugstore industry, holding 15.6% of industry market cap.
- Peer revenue share: Cardinal Health Inc accounted for 16.3% of combined revenue among its tracked peer group, up from 15.5% a year earlier.
- Peer differentiation: Revenue per employee of $3.92M compares with $1.60M for the peer group (2.5x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
CAH Sales vs. its Competitors, Q3 2026
Cardinal Health Inc reported revenue growth of 11.05 % year on year in Q3 2026, above its competitors' combined revenue growth of 5.28 %.
With a net margin of 0.62 %, Cardinal Health Inc reported lower profitability than its competitors (3.06 %).
Cardinal Health Inc generated 16.25 % of the combined sales of its peer group, up from 15.54 % a year earlier.
Cardinal Health Inc vs. its Competitors, Q3 2026
Revenue growth, year on year
Net income growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Cardinal Health Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Cardinal Health Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (9) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (7) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (7) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Cardinal Health Inc's competitor groups requires a Commercial License.
For context: the Pharmacy Services & Retail Drugstore industry grew revenue 6.7% year over year, combined, vs 11.1% for Cardinal Health Inc. Cardinal Health Inc's share of combined industry revenue moved from 13.63% to 14.19%, a gain of 0.56 percentage points.
Cardinal Health Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Cardinal Health Inc | Yes | Yes | Yes | No |
| Competitors combined (21) | ||||
| High-Confidence Competitors (11) | ||||
| Similar-Size Competitors (8) | ||||
| Similar Growth & Profitability (8) | 100.00 % (8 of 8) | 87.50 % (7 of 8) | 87.50 % (7 of 8) | 0.00 % (0 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
CAH Stock Performance relative to its Competitors
CAH Stock Performance relative to High-Confidence Competitors
CAH Stock Performance relative to Similar-Size Competitors
CAH Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Amneal Pharmaceuticals Inc | 282.9% | Outperformed |
| 2 | Diversified Healthcare Trust | 282.9% | Outperformed |
| 3 | Thermo Fisher Scientific Inc | 282.9% | Outperformed |
| 4 | West Pharmaceutical Services Inc | 282.9% | Outperformed |
| 5 | Herbalife Ltd | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Cardinal Health Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Cardinal Health Inc's Comment on Competition and Industry Peers
We operate in a highly competitive environment in the distribution of pharmaceuticals and related healthcare services. We also operate in a highly competitive environment in the development, manufacturing and distribution of medical and surgical products. We compete on many levels, including service offerings, support services, breadth of product lines and price.
In the Pharmaceutical segment, we compete with wholesale distributors with national reach (including McKesson Corporation and AmerisourceBergen Corporation), regional wholesale distributors, self-warehousing chains, specialty distributors, third-party logistics companies, companies that provide services supporting the development, marketing, distribution and payment for specialty pharmaceutical products and nuclear pharmacies, among others. In addition, the Pharmaceutical segment has experienced competition from a number of organizations offering generic pharmaceuticals, including telemarketers. We also compete with manufacturers that sell all or part of their product offerings directly.
In the Medical segment, we compete with many different national medical product distributors, including Owens & Minor, Inc., McKesson Corporation and Medline Industries, Inc. We also compete with regional medical product distributors and companies that distribute medical products to patients in the home as well as third-party logistics companies. In addition, we compete with manufacturers that sell all or part of their product offerings directly. Competitors of the Medical segment’s manufacturing and procedural kit businesses include diversified healthcare companies as well as companies that are more focused on specific product categories.
Publicly Traded Peers of Cardinal Health Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Cardinal Health Inc | 51,988.44 | 250,735.00 |
| Thermo Fisher Scientific Inc | 251,760.60 | 46,336.00 |
| Danaher Corporation | 160,858.71 | 25,107.00 |
| Cvs Health Corporation | 113,062.95 | 415,086.00 |
| Mckesson Corporation | 102,069.77 | 410,983.00 |
| Cencora Inc | 59,359.31 | 328,680.02 |
| SUBTOTAL | 893,820.75 | 1,568,353.06 |
Sign in to see all competitors of Cardinal Health Inc .
Sources: Cardinal Health Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Cardinal Health Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Cardinal Health Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Avinger Inc | Named by the company | 85% |
| McKesson Corporation | Named by the company | 85% |
| Alpha Pro Tech Ltd | Named by the company | 85% |
| Solventum Corporation | Named by the company | 85% |
| Guardian Pharmacy Services Inc | Named by the company | 85% |
| Viatris Inc | Named by the company | 85% |
| Accendra Health inc | Named by the company | 85% |
| OMI | Named by the company | 85% |
| Avanos Medical Inc | Named by the company | 85% |
| Cardinal Ethanol Llc | Named by the company | 85% |
| Medline Industries | Named by the company | 85% |
| Specialty Solutions | Named by the company | 85% |
| Conmed Corporation | Named by the company | 85% |
| Scienture Holdings Inc | Named by the company | 85% |
| Amneal Pharmaceuticals Inc | Named by the company | 85% |
| Diversified Healthcare Trust | Named by the company | 85% |
| Cencora Inc | Named by the company | 85% |
| Adapthealth Corp | Named by the company | 85% |
| Owens Corning | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Cardinal Health Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Cardinal Health Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Cardinal Health Inc | Pharmaceutical and Specialty Solutions 92.08 % |
| Thermo Fisher Scientific Inc | Clinical Research 19.98 % |
| Danaher Corporation | Diagnostics 39.36 % |
| Cvs Health Corporation | Health Services 48.03 % |
| Mckesson Corporation | North American Pharmaceutical 83.45 % |
| Cencora Inc | U.S. Healthcare Solutions 87.76 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Cardinal Health Inc .
Cardinal Health Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Cardinal Health Inc | 51,988 | 3,923,865 | 24,225 |
| Thermo Fisher Scientific Inc | 251,761 | 370,688 | 55,912 |
| Danaher Corporation | 160,859 | 418,450 | 66,733 |
| Cvs Health Corporation | 113,063 | 1,383,620 | 16,283 |
| Mckesson Corporation | 102,070 | 8,058,490 | 103,922 |
| Cencora Inc | 59,359 | 6,444,706 | 50,046 |
| PEERS TOTAL | 841,832 | 1,598,409 | 30,686 |
Sign in to see all peers for Cardinal Health Inc .
Cardinal Health Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Cardinal Health Inc | United States 99.35 % |
| Thermo Fisher Scientific Inc | North America 51.27 % |
| Danaher Corporation | North America 39.49 % |
| Becton Dickinson And Company | United States 61.88 % |
| Baxter International Inc | Non-US 1.44 % |
| Owens Corning | North America 88.17 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Cardinal Health Inc .
Cardinal Health Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 14 companies in Cardinal Health Inc's industry classification, broader than the peer set above. Market cap in millions of $.Cardinal Health Inc ranks #4 of 14 companies by market capitalization in its industry, holding 15.61 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 2,686, indicating a highly concentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Cvs Health Corporation | 114,504 | 34.20 % |
| 2 | Mckesson Corporation | 103,404 | 30.88 % |
| 3 | Cencora Inc | 59,677 | 17.82 % |
| 4 | Cardinal Health Inc | 52,279 | 15.61 % |
| 5 | Guardian Pharmacy Services Inc | 1,234 | 5.2% |
| 6 | Herbalife Ltd | 1,234 | 5.2% |
| 7 | 111 Inc | 1,234 | 5.2% |
| 8 | Nu Skin Enterprises Inc | 1,234 | 5.2% |
| 9 | Zerostack Corp | 1,234 | 5.2% |
| 10 | Petmed Express Inc | 1,234 | 5.2% |
Market cap and industry share for the rest of Cardinal Health Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-28.
Cardinal Health Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 1 | Cvs Health Corporation | 114,504 | 19.25 % |
| 2 | Mckesson Corporation | 103,404 | 17.78 % |
| 3 | Cencora Inc | 59,677 | 2.97 % |
| 4 | Cardinal Health Inc | 52,279 | 48.71 % |
| 5 | Guardian Pharmacy Services Inc | 1,234 | 12.3% |
| 6 | Herbalife Ltd | 1,234 | 12.3% |
| 7 | 111 Inc | 1,234 | 12.3% |
| 8 | Nu Skin Enterprises Inc | 1,234 | 12.3% |
| 9 | Zerostack Corp | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Cardinal Health Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-28. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Cardinal Health Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Pharmacy Services & Retail Drugstore industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (28 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 3.76 % | 21.82 % (avg) | -18.1 pp |
| Operating Margin | 0.92 % | industry median | -0.3 pp |
| EBITDA Margin | 1.29 % | -3.58 % (avg) | +4.9 pp |
| Capital Intensity (Capex / Revenue) | 0.25 % | 1.20 % (avg) | -0.9 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Cardinal Health Inc's Valuation vs Competitive Position
Valuation multiples vs the Pharmacy Services & Retail Drugstore industry average (28 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 33.0x | 29.8x | +3.2x |
| EV / EBITDA | 17.1x | 15.4x | +1.7x |
| P/B | -19.0x | 3.5x | -22.6x |
| Return on Equity | -58.03 % | industry aggregate | -74.52 % |
| Return on Invested Capital | 74.35 % | 8.49 % (avg) | 65.86 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Cardinal Health Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 7.03 % | 5.44 % | 4.54 % | 9.48 % | 12.68 % | 11.99 % | 2.78 % | 10.13 % |
| Operating Margin | 0.55 % | -2.80 % | 0.43 % | 0.06 % | -0.02 % | 0.54 % | 0.85 % | 1.04 % |
| Return on Invested Capital | 3.28 % | -20.69 % | 3.49 % | 0.54 % | -0.64 % | -59.43 % | -98.15 % | 73.59 % |
| P/E | 18.8x | - | 11.6x | 26.3x | - | 41.3x | 22.6x | 29.6x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Cardinal Health Inc's Strategic Group Map
Every company in Cardinal Health Inc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Cardinal Health Inc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Cardinal Health Inc's BCG Growth-Share Matrix
Relative market share (vs Cardinal Health Inc's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Cardinal Health Inc falls in the Dog quadrant: relative market share of 0.46x vs its largest competitor, in an industry growing revenue -4.1% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Cardinal Health Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | Low | Industry HHI of 2,686 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.25 % vs industry average 1.20 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Cardinal Health Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Cardinal Health Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Cardinal Health Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Cardinal Health Inc falls in the Medium attractiveness / Medium strength cell: Selective.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Cardinal Health Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Return on equity 74.5 points below the industry aggregate.
- Latest-quarter revenue run-rate is decelerating (-2.8% annualized vs trailing 12 months).
- Low relative market share vs the industry leader (0.46x).
Opportunities
- A meaningful share of tracked competitors (30.00 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-4.7% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Cardinal Health Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Cardinal Health Inc | 0.10 | 0.93 | - |
| Thermo Fisher Scientific Inc | 0.32 | 1.62 | 0.78 |
| Danaher Corporation | - | 1.73 | 0.40 |
| Cvs Health Corporation | 0.11 | 0.85 | 0.83 |
| Mckesson Corporation | 0.07 | 0.88 | - |
| Cencora Inc | 0.06 | 0.91 | 3.87 |
Sign in to see all peers for Cardinal Health Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Cardinal Health Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Cardinal Health Inc | Q1 2026 | +11.0 % | -25.2 % |
| Thermo Fisher Scientific Inc | Q2 2026 | +10.5 % | +7.6 % |
| Danaher Corporation | Q2 2026 | +5.5 % | +56.8 % |
| Cvs Health Corporation | Q2 2026 | +7.3 % | +195.7 % |
| Mckesson Corporation | Q2 2026 | +7.7 % | +24.2 % |
| Cencora Inc | Q1 2026 | +3.8 % | +127.1 % |
| PEERS TOTAL | +7.1 % | +48.7 % |
Sign in to see all peers for Cardinal Health Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Cardinal Health Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Cardinal Health Inc | Q1 2026 | +10.8 % | - |
| Thermo Fisher Scientific Inc | Q2 2026 | +142.5 % | +53.1 % |
| Danaher Corporation | Q2 2026 | +10.0 % | +8.5 % |
| Cvs Health Corporation | Q2 2026 | +9.0 % | +13.8 % |
| Mckesson Corporation | Q2 2026 | +7.6 % | -19.6 % |
| Cencora Inc | Q1 2026 | +3.3 % | - |
Sign in to see all peers for Cardinal Health Inc .
Cardinal Health Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Cardinal Health Inc | 2.84% | 26.79% | - |
| Thermo Fisher Scientific Inc | 6.36% | 7.71% | 13.37% |
| Danaher Corporation | 4.72% | 5.44% | 7.66% |
| Cvs Health Corporation | 1.92% | 2.81% | 6.39% |
| Mckesson Corporation | 6.43% | 35.05% | - |
| Cencora Inc | 3.31% | 14.72% | 109.91% |
Sign in to see all peers for Cardinal Health Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Cardinal Health Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Cardinal Health Inc | 33.74 | 0.21 |
| Thermo Fisher Scientific Inc | 36.52 | 5.43 |
| Danaher Corporation | 40.45 | 6.41 |
| Cvs Health Corporation | 23.12 | 0.27 |
| Mckesson Corporation | 23.01 | 0.25 |
| Cencora Inc | 23.28 | 0.18 |
| PEERS AVERAGE | 33.30 | 0.57 |
Sign in to see all peers for Cardinal Health Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.